CG Oncology, Inc. (CGON) income statement
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$80.00+1.06 (+1.34%)
Close on Nov 18, 2026Market cap $7.09BP/E –Yield –
CG Oncology, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -4293.5%
- Net margin
- -3851.1%
- Return on equity, FY2025
- -21.7%
Financial strength
- Current ratio
- 21.70
- Debt to equity
- 0.00
- Debt to assets
- 0.3%
- Cash to current liabilities
- 60.8%
Valuation
- P/E ratio
- –
- Price to sales
- 1150.05
- Price to book
- 7.16
- Dividend yield
- –
See a number that looks wrong?